Last reviewed · How we verify
DPP-4 inhibitor + metformin group
This combination inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels while metformin reduces hepatic glucose production, together improving glycemic control in type 2 diabetes.
This combination inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels while metformin reduces hepatic glucose production, together improving glycemic control in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | DPP-4 inhibitor + metformin group |
|---|---|
| Sponsor | Beni-Suef University |
| Drug class | DPP-4 inhibitor + biguanide combination |
| Target | DPP-4 enzyme; metformin acts on multiple targets including mitochondrial glycerophosphate dehydrogenase |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
DPP-4 inhibitors prolong the action of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion in response to elevated blood glucose. Metformin decreases hepatic gluconeogenesis and improves insulin sensitivity in peripheral tissues. The combination provides complementary mechanisms to lower fasting and postprandial glucose levels.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disturbance (nausea, diarrhea)
- Headache
- Nasopharyngitis
- Lactic acidosis (rare, metformin-related)
Key clinical trials
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus (PHASE1, PHASE2)
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes (PHASE3)
- Empa PASS on Urinary Tract Malignancies
- Effect of Ertugliflozin on Cardiac Function in Diabetes (PHASE3)
- Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.
- Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DPP-4 inhibitor + metformin group CI brief — competitive landscape report
- DPP-4 inhibitor + metformin group updates RSS · CI watch RSS
- Beni-Suef University portfolio CI